Programmed Death-Ligand 1 Expression across Multiple Assays in Ovarian Cancer: A Comparative Analysis
Cancer Research and Treatment · 15.04.2026 · 58 (2) · 622-631
DOI: 10.4143/crt.2025.202 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2026. Verfasst von Eun Bi Jang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: B7-H1 Antigen, Ovarian Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare.
Abstract (Originalsprache)
PurposeOvarian cancer presents significant treatment challenges due to its aggressive nature and poor response to immune checkpoint inhibitors (ICIs). The lack of standardized programmed cell death-ligand 1 (PD-L1) assays and cut-off values complicates clinical decision-making. We evaluated the concordance among commonly used PD-L1 assays and assessed changes in the expression of PD-L1 following chemotherapy.Materials and MethodsTissue samples from 29 patients with ovarian cancer were analyzed using five validated PD-L1 immunohistochemistry assays: Dako 22C3, Ventana SP263, Ventana SP142, Dako 28-8, and Ventana 22C3. PD-L1 positivity was assessed using a combined positive score (CPS), immune cell, or tumor proportion score at 1%, 5%, and 10% cut-offs. Concordance rates, including overall percent agreement and Cohen’s kappa coefficient, were analyzed. In addition, changes in the expression of PD-L1 pre- and postchemotherapy were evaluated.ResultsPositivity rates ranged from 15.8% (SP142) to 29.8% (Dako 22C3 and SP263) at the 1% CPS cut-off. SP142 consistently exhibited the lowest concordance, whereas Dako 22C3 displayed high agreement with SP263, 28-8, and Ventana 22C3. Chemotherapy increased PD-L1 positivity, with 28% of patients converting from negative to positive.ConclusionThe expression of PD-L1 in ovarian cancer varies across assays and scoring methods, emphasizing the need for standardized testing protocols. Increased PD-L1 expression post-chemotherapy underscores the importance of assessing its status at appropriate times to guide ICI therapy. Larger studies are required to validate these findings and refine clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
- Department of Pathology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
Förderung
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
Zitieren
APA
Jang, E. B., So, K. A., Kim, W. Y., Lim, S. D., Kim, T. J., Bang, H., & Kim, W. S. (2026). Programmed Death-Ligand 1 Expression across Multiple Assays in Ovarian Cancer: A Comparative Analysis. Cancer Research and Treatment, 58(2), 622-631. https://doi.org/10.4143/crt.2025.202
Vancouver
Jang EB, So KA, Kim WY, Lim SD, Kim TJ, Bang H, et al. Programmed Death-Ligand 1 Expression across Multiple Assays in Ovarian Cancer: A Comparative Analysis. Cancer Research and Treatment. 2026;58(2):622-631. doi:10.4143/crt.2025.202
BibTeX
@article{Jang2026,
author = {Jang, Eun Bi and So, Kyeong A and Kim, Wook Youn and Lim, So Dug and Kim, Tae Jin and Bang, Heejin and Kim, Wan Seop},
title = {Programmed Death-Ligand 1 Expression across Multiple Assays in Ovarian Cancer: A Comparative Analysis},
journal = {Cancer Research and Treatment},
year = {2026},
volume = {58},
number = {2},
pages = {622--631},
doi = {10.4143/crt.2025.202}
}
EUVIMED